Polypid Shield’s Phase 3 Results: Paradigm Shift in Surgical Infection Prevention
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial, showing D-PLEX100 significantly reduced surgical site...
Jon Napitupulu
Unprecedented 76-Week Barzolvolimab Results in Chronic Urticaria
Celldex released 76-week data from a Phase 2 trial of barzolvolimab for chronic spontaneous urticaria (CSU). Seven months after...
Revumenib Data from BEAT AML Trial Published in JCO & Presented at EHA 2025
Syndax Pharmaceuticals announced positive results from the BEAT AML trial of revumenib combined with venetoclax and azacitidine (ven/aza) in...
Apex Labs Expands Macrodose Psilocybin PTSD Trial
Apex Labs Ltd. received approval from Israel’s Ministry of Health to expand its phase 2b clinical trial, SUMMIT-90, for...
Neurostimulation Trial for Opioid Disorder Shows Promising Results
Spark Biomedical concluded enrollment for its pivotal clinical trial using transcutaneous auricular neurostimulation (tAN) to improve treatment retention for...
Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Promising Data: Alrizomadlin in Solid Tumors
Ascentage Pharma released Phase II clinical trial data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 2025 ASCO Annual...
RECELL Reduced Hospital Stays: Largest Real-World Analysis
AVITA Medical highlighted data from the British Burn Association Annual Meeting showing that RECELL, its spray-on skin cell technology,...
Polypid’s Shield II Phase 3 Trial Delivers Groundbreaking Results
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial of D-PLEX100 for preventing surgical site...
Humacyte’s AV Access Study Shows Promising Results
Humacyte, a biotech company focused on bioengineered human tissues, presented positive Phase 3 clinical trial results for their acellular...